Background: Compositional differences in the bronchial bacterial microbiota have been associated with asthma, but it remains unclear whether the findings are attributable to asthma, to aeroallergen sensitization, or to inhaled corticosteroid treatment. Objectives: We sought to compare the bronchial bacterial microbiota in adults with steroid-naive atopic asthma, subjects with atopy but no asthma, and nonatopic healthy control subjects and to determine relationships of the bronchial microbiota to phenotypic features of asthma. Methods: Bacterial communities in protected bronchial brushings from 42 atopic asthmatic subjects, 21 subjects with atopy but no asthma, and 21 healthy control subjects were profiled by using 16S rRNA gene sequencing. Bacterial composition and communitylevel functions inferred from sequence profiles were analyzed for between-group differences. Associations with clinical and inflammatory variables were examined, including markers of type 2-related inflammation and change in airway hyperresponsiveness after 6 weeks of fluticasone treatment. Results: The bronchial microbiome differed significantly among the 3 groups. Asthmatic subjects were uniquely enriched in members of the Haemophilus, Neisseria, Fusobacterium, and Porphyromonas species and the Sphingomonodaceae family and depleted in members of the Mogibacteriaceae family and Lactobacillales order. Asthma-associated differences in predicted bacterial functions included involvement of amino acid and short-chain fatty acid metabolism pathways. Subjects with type 2-high asthma harbored significantly lower bronchial bacterial burden. Distinct changes in specific microbiota members were seen after fluticasone treatment. Steroid responsiveness was linked to differences in baseline compositional and functional features of the bacterial microbiome.
Conclusion: Even in subjects with mild steroid-naive asthma, differences in the bronchial microbiome are associated with immunologic and clinical features of the disease. The specific differences identified suggest possible microbiome targets for future approaches to asthma treatment or prevention. (J Allergy Clin Immunol 2017;140:63-75.)
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Recent culture-independent studies have documented that the composition of commensal lower respiratory tract bacteria (microbiota) differs between asthmatic and healthy adults. [1] [2] [3] [4] [5] [6] Additionally, phenotypic features of asthma, such as measures of airway hyperresponsiveness, asthma control, and transcriptional response to steroids, correlate with patterns of bronchial microbiota composition. 4, 5 Although different studies have reported asthma-associated enrichment (higher relative abundance) of different taxa (ie, bacteria-derived 16S ribosomal RNA gene sequences that exhibit an operator-defined level of sequence homology [typically 97%]), enrichment in members of the phylum Proteobacteria is a repeating signature. Asthmatic subjects in most previous studies were treated with inhaled corticosteroids (ICSs), casting some uncertainty on whether the findings reflect the effects of ICS treatment or of asthma itself. Similarly, many asthmatic patients are atopic, 7, 8 raising the question of whether asthma-associated differences in respiratory microbiota are 9, 10 Collectively, these considerations indicate a need to elucidate differences in the bronchial microbiota associated with asthma versus atopy and with important phenotypic features of this disease, such as the level of type 2 (T2) inflammation and responsiveness to ICS treatment.
Accordingly, we compared the bronchial bacterial microbiome among adults with mild steroid-naive atopic asthma, subjects with atopy without asthma, and healthy nonatopic nonasthmatic control subjects. We hypothesized that specific compositional and functional differences in bronchial microbiota are associated with asthma and with distinguishing phenotypic features of the disease, including evidence of T H 2 inflammation and responsiveness to ICS treatment.
METHODS

Study population and sample collection
This study was conducted at 9 sites in the National Heart, Lung, and Blood Institute AsthmaNet network by using a standardized bronchoscopy protocol for sample collection. Of 186 adults screened, 84 subjects were enrolled (see Fig E1, A and B, in this article's Online Repository at www.jacionline.org): 42 atopic asthmatic subjects (AAs), 21 atopic nonasthmatic subjects (ANAs), and 21 nonatopic healthy control subjects (HCs). Atopy was defined based on serologic evidence (>0.35 kU/L) of sensitivity to 1 or more of 12 aeroallergens (specific IgE measured by means of ImmunoCAP, Thermo Scientific, Waltham, Mass; see Table E1 in this article's Online Repository at www.jacionline.org). Asthma was confirmed based on measurement of airway hyperresponsiveness (methacholine PC 20 < _8 mg/mL or FEV 1 improvement > _12% after albuterol). At enrollment, asthmatic subjects had been clinically stable for 3 months and had an Asthma Control Questionnaire score of less than 1.5 11 without use of a controller medication. Exclusion criteria included a history of smoking, respiratory tract infection within 6 weeks, or antibiotic use within 3 months of enrollment (see the Methods section in this article's Online Repository at www.jacionline.org).
Samples processed for microbiota analysis included oral wash (OW) samples, 12 a saline flush (10 mL) of the bronchoscope suction channel (scopeflush), and protected bronchial brushings (BBs; see Fig E1 , C, and see the Methods section in this article's Online Repository). AAs were further randomized in a 2:1 ratio to treatment with inhaled fluticasone propionate (250 mg; GlaxoSmithKline, London, United Kingdom) or placebo twice daily for 6 weeks and reassessed after treatment. Each subject signed informed consent forms approved by their center's institutional review board; a National Heart, Lung, and Blood Institute-appointed Data Safety Monitoring Board oversaw the study conduct.
Nucleic acid extraction and quantitation of 16S rRNA gene copy number Nucleic acids from OW samples and 3 BB samples were extracted, as previously described, 5, 12 by using a modified bead-beating protocol and the AllPrep kit (Qiagen, Hilden, Germany). 16S rRNA gene copy number was assessed by means of quantitative PCR with universal primers (see the Methods section in this article's Online Repository).
16S rRNA-based sequencing and raw data processing
For BB and OW samples, variable region 4 (V4) of the 16S rRNA gene was amplified by using the primer combination 515F/806R 13, 14 and sequenced on the Illumina MiSeq platform (Illumina, San Diego, Calif). By using chimerachecked and quality-filtered sequence reads (see the Methods section in this article's Online Repository), a 97% sequence homology cutoff was used to define bacterial taxa (also referred to as operational taxonomic units [OTUs] ) and classified by using the Greengenes database. 15 A phylogenetic tree was built with FastTree 16 and used to compute the Faith phylogenetic diversity 17 of samples by using an OTU table multiply rarefied to 52,317 sequences per sample (see the Methods section in this article's Online Repository). All sequence data related to this study are available from the European Nucleotide Archive (ENA) under accession number PRJEB15534.
''Three-gene mean'' bronchial epithelial signature of T2 inflammation Expression levels of 3 bronchial epithelial genes (CLCA1, SERPINB2, and POSTN) previously shown to be induced by IL-13 18, 19 were measured by using RNA extracted in parallel with DNA in this study to calculate the ''three-gene mean'' (TGM) score for each participant.
20 T2-high asthma was defined by TGM scores of 1.117 or greater (2 SDs greater than the average TGM score in HCs), as confirmed by using unsupervised cluster and principal component analysis.
Statistical analyses
We applied principal coordinates analyses on an unweighted UniFrac distance matrix and PERMANOVA 21 to identify the determinants of variation in bacterial community b-diversity. A linear mixed-effects model 22 was used to examine relationships between paired OW and BB microbiota; negative binomial and zero-inflated negative binomial regression models [23] [24] [25] [26] corrected for false discovery (q < 0.1, Benjamini-Hochberg) were used to identify OTUs differentially abundant between subject groups and paired samples, respectively. We applied Phylogenetic Reconstruction of Unobserved States (PICRUSt) to predict functional capacities of the microbiota 27 and negative binomial regression to compare inferred functional pathway predictions across groups. Procrustes analysis 13 was used to explore the strength of relationships between paired samples in the AA group (see the Methods section in this article's Online Repository).
RESULTS
Study group characteristics
AAs had mild well-controlled disease and significantly higher serum total IgE levels and blood and sputum eosinophil counts (Table I and see Fig E2 , A-C, in this article's Online Repository at www.jacionline.org) than HCs. Compared with the ANAs, asthmatic subjects had significantly higher serum IgE levels; were sensitized to more of the aeroallergens tested (Table I) ; were more likely to be sensitive to cat, dog, and mouse (see Table E1 ); and were more likely to report a history of allergic rhinitis and eczema (see Table E2 in this article's Online Repository at www. jacionline.org). However, they did not exhibit significant differences in environmental exposures, as assessed by questionnaire (see Table  E3 in this article's Online Repository at www.jacionline.org).
Bacterial microbiota in BB samples is compositionally distinct from that in OW samples
To evaluate mucosa-associated bronchial microbiota, we focused on protected BB samples. Sequence-based bacterial J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 1 community analysis could be performed in the same proportion (67%) of samples collected in each of the 3 groups (see Fig E1, D and E). Samples that could not be sequenced had lower bacterial burden, as indicated from 16S rRNA (P < .0001; see Fig E2, D) , despite recovery of similar mammalian cell burden, as assessed by quantifying b-actin copy number (see the Methods section in this article's Online Repository). Subjects with insufficient 16S rRNA amplicons for microbiota profiling were younger (median, 28 [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] vs 34 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] years; P 5 .03) but did not differ in any other characteristics measured.
Potential oral contamination of BB samples was evaluated by comparing a random subset of 30 BB-paired scope-flush samples. Bacterial burden of scope-flushes for BB samples with sufficient 16S rRNA for sequencing was indistinguishable from those unable to be sequenced (P > .1; see Fig E2, E) . Additionally, principal coordinates analysis of bacterial community composition in paired OW and BB samples showed these 2 niches to be compositionally distinct (b 5 0.31 and P < .0001, linear mixed-effects model; Fig 1, A) , with BB samples exhibiting lower phylogenetic diversity (Faith index: P < .0001; Fig 1, B) .
Features of the bronchial bacterial microbiota and distinct combinations of specific bacterial taxa are associated with atopic asthma or atopy alone a-Diversity indices, such as richness (number of observed taxa), Shannon diversity, and evenness, as well as bacterial burden, did not differ among the groups (see Fig E2, F-I ). However, phylogenetic diversity (Faith index) tended to be higher in AAs compared with that in HCs (P 5 .06; Fig 1, C) . Because this index weights the phylogenetic relatedness of the bacteria detected, this observation suggests that the bronchial airways of AAs harbor more phylogenetically diverse bacterial communities. Although phylogenetic diversity in ANAs also appeared to be greater than that in HCs (Fig 1, C) , the difference fell short of significance. Overall, intersubject bacterial community composition (b-diversity) was highly heterogeneous across subjects (see Fig E3, A, in this article's Online Repository at www.jacionline.org). This was significantly related to bacterial richness independent of study group (see Fig E3, B-E) but was not associated with any of the clinical measures or environmental exposures evaluated in this study (Table I and  see Tables E1-E3 ). Compositional variability in bronchial bacterial microbiota was significantly greater within the asthmatic group (P < .001, weighted UniFrac distance F-test; see Fig E3, F) , indicating a greater degree of bacterial community heterogeneity in this group.
After these initial assessments for differences in overall bacterial community composition, we conducted OTU-level analyses to determine whether the relative abundance of specific taxa differed significantly across groups; 76 taxa were found to do so in the AA versus HC comparison (see Table E4 in this article's Online Repository at www.jacionline.org). Phylum-level differences in AAs (Fig 2, A, and see Fig E4, A, in this article's Online Repository at www.jacionline.org) included significant enrichment for members of the Bacteroidetes (Prevotella species), Fusobacteria (Fusobacterium species), Actinobacteria (Actinomyces species), and Proteobacteria (Haemophilus and Neisseria species), the latter previously associated with more severe, ICS-requiring asthma. [2] [3] [4] [5] [6] 28 Conversely, asthmatic subjects showed reduced relative abundance of members of the Fusobacteria (Leptotrichia species), Proteobacteria (Actinobacillus species), and Firmicutes (Lactobacillus species). ANAs also demonstrated significant differences in the relative abundance of 100 taxa compared with HCs (see Table E5 , B, in this article's Online Repository at www.jacionline.org). The All values are medians (interquartile ranges). Statistical significance was determined by using the following tests: kKruskal-Wallis, {x 2 , or #Mann-Whitney for AA versus ANA comparison. ACQ, Asthma Control Questionnaire; NS, not significant. *Number of exacerbations requiring oral steroids in the past 5 years: 0 exacerbations, 38 subjects; 1 exacerbation, 3 subjects; and 2 exacerbations, 1 subject.
Methacholine challenge was stopped at 32 mg/dL, and PC 20 values for these subjects were censored. àFor between-group statistical comparisons, see Fig E2, A-C.
§Number of positive specific IgE measurements (sIgE >0.35 kU/L) from a total of 12 aeroallergens tested by using the ImmunoCAP assay (for breakdown of specific aeroallergens, see Table E1 ).
taxa most relatively enriched in ANAs included members of the Proteobacteria (Aggregatibacter and Haemophilus species), Firmicutes (Granulicatella species), and Actinobacteria (Corynebacterium species) phyla (Fig 2, B , and see Fig E4, B) ; those depleted included members of the phylum Bacteroidetes (Porphyromonas and Prevotella species).
We noted that the ANAs shared 26% and 29% of taxa that were also relatively enriched or depleted in AAs when compared with HCs. Despite these similarities, OTU-level analysis identified 103 taxa that differed significantly between the AA and ANA groups (Fig 2, C, and see Fig E4, C, Table E6 in this article's Online Repository at www.jacionline.org). To pinpoint bacteria discretely associated with asthma, we evaluated which taxa among those that distinguished AAs from HCs also distinguished AAs from ANAs (Fig 3) . By using this approach, asthma-associated taxa included members of the Haemophilus (OTU4406393), Fusobacterium (OTU4405869; OTU2438396), Neisseria (OTU1304), and Porphyromonas (OTU495451) species and the Sphingomonodaceae family (OTU8331815), whereas taxa negatively associated with asthma included members of the Mogibacteriaceae family (OTU4335578) and Lactobacillales order (OTU4480189; OTU4469032). The same approach also identified taxa specific to atopy alone, which included enrichment in Aggregatibacter (OTU4432431), Corynebacterium (OTU1015518; OTU 495067), and Prevotella (OTU4372058; OTU134265) species (Fig 3) . Of the taxa identified as specifically associated with either asthma or atopy alone, a subset exhibited strong and significant correlations with features of atopy (IgE levels and blood and sputum eosinophil counts); these associations were distinct in the 2 atopic groups. For example, specific taxa uniquely enriched in AAs, belonging to the Sphingomonodaceae and Fusobacteria families, were positively associated with all 3 markers of atopy, whereas of those specifically enriched in ANAs, Sharpea and Prevotella species (OTU1052181; OTU134265) correlated with IgE levels and blood eosinophil counts, respectively (Fig 3) . These data indicate that although taxonomic overlap exists between AAs and ANAs, discrete bacterial enrichments characterize these groups, a subset of which are associated with biomarkers of atopic disease.
We further explored whether predicted functions of the bronchial bacterial microbiome differed among the 3 groups by using PICRUSt, 27 an algorithm that predicts bacterial metagenomes in silico from 16S rRNA sequence. This analysis revealed significant differences across groups (Fig 4) . Predicted bacterial gene functions enriched in AAs included those involved in metabolism of amino acids and carbohydrates, especially of short-chain fatty acids (SCFAs), such as butanoate and propanoate (more commonly known as butyrate and propionate, respectively). Also noteworthy was a relative depletion in predicted bacterial functions involved in LPS biosynthesis among asthma-associated bacterial communities.
T2-high asthma is associated with reduced bronchial bacterial burden
TGM scores were higher in AAs (Fig 5, A) and, consistent with prior reports, 20,29 correlated positively with serum IgE levels (r S 5 0.36, P < .01) and blood and sputum eosinophil counts (r S 5 0.32 and r S 5 .37, respectively; P < _ .01) and correlated negatively with FEV 1 (r S 5 20.45, P < .005) and PC 20 (r S 5 20.41, P < .005) values. Ten of 40 AAs had T2-high asthma and exhibited significantly higher Asthma Control Questionnaire scores, serum IgE levels, and blood and sputum eosinophil counts and younger age than subjects with T2-low asthma (see Table E7 in this article's Online Repository at www.jacionline.org). Subjects with T2-high asthma demonstrated significantly lower bronchial bacterial burden than subjects with T2-low asthma ( Fig 5, C) ; bacterial burden also was negatively correlated with TGM scores across all asthmatic subjects (r S 5 20.43, P < .01) independent of age (general linear model: P 5 .03). Because of their low bacterial burden, BB samples from only 4 subjects with T2-high asthma could be sequenced for profiling, an insufficient sample size to allow meaningful assessment of differences in bacterial microbiota composition between those with T2-high asthma and those with T2-low asthma.
ICS responsiveness is associated with distinct features of the bronchial bacterial microbiota present before treatment
We hypothesized that differences in baseline airway microbiota characteristics might be associated with ICS responsiveness, which was defined as a 2-fold or greater increase in methacholine PC 20 after ICS treatment. Of the asthmatic subjects included, 15 were classified as ICS responders and 10 as nonresponders, and 3 were excluded because PC 20 measurement was not performed (see Fig E5, A and B) . Compared with nonresponders, ICS responders did not differ in PC 20 values, serum IgE levels, and blood and sputum eosinophil counts or bronchial burden at baseline but did have lower FEV 1 values and a trend toward a higher TGM score (P < .08; see Fig E5 , C, and Table E8 in this article's Online Repository at www.jacionline.org), which decreased after treatment (P < .05; see Fig E4, D) .
The baseline composition of profiled bronchial bacterial microbiota in ICS responders (n 5 10) differed from that in nonresponders (n 5 5; unweighted UniFrac PERMANOVA: R 2 5 0.13, P 5 .01) and was significantly more similar to that of HCs (Fig 6, A) . Bacterial families enriched at baseline in ICS nonresponders included Microbacteriaceae, Pasteurellaceae (eg, asthma-associated Haemophilus OTU4406393), and several others (Fig 6, C , and see Table E9 in this article's Online Repository at www.jacionline.org). Conversely, bacterial families enriched at baseline in ICS responders included Streptococcaceae, Fusobacteriaceae, and Sphingomonodaceae. Compared with ICS responders, the predicted functions of bacterial communities of nonresponders were enriched in xenobiotic biodegradation pathways (Fig 6, D , and see Table  E10 in this article's Online Repository at www.jacionline.org), implicating potential enhanced capacity for synthetic chemical degradation.
After 6 weeks of ICS versus placebo treatment, we found no significant changes in bacterial burden or phylogenetic diversity in the AA group (see Fig E6, A and B, in this article's Online Repository at www.jacionline.org). Bacterial community analysis in paired samples before and after treatment was limited because several subjects did not have sufficient 16S rRNA to obtain sequence data at both time points. Nonetheless, we reasoned that ICS exposure might have distinct effects on the microbiotas of nonresponders and ICS responders 2 and explored ICS-induced compositional changes in the latter more predominant group. No significant differences were seen in the magnitude of changes (b-diversity assessed based on unweighted UniFrac distance) between paired samples (n 5 8 each in placebo or ICS-treated responders; see Fig E6, C-E) . At the taxon level, however, ICS treatment resulted in increased relative abundance of Microbacteriaceae and Neisseria and Moraxella species and depletion of a specific Fusobacterium, which was not observed with the placebo treatment (Fig 6, D , and see Tables E11 and  E12 in this article's Online Repository at www.jacionline.org).
Unfortunately, we could not analyze compositional changes in ICS nonresponders because only 2 subjects in this subgroup had sufficient 16S rRNA in both pretreatment and posttreatment samples.
DISCUSSION
Our findings show compositional and predicted functional differences in the bronchial bacterial microbiomes of AAs, ANAs, and HCs. An important implication of these findings is that control for allergic sensitization is necessary in studies aimed at understanding differences in the respiratory microbiome associated with asthma. Despite overlap in bacterial genera significantly associated with both atopic groups, our study identified specific bacterial taxa whose relative enrichment or depletion was discretely associated with asthma. Analyses based on metagenomic inference further suggest that genes for pathways involved in the metabolism of SCFAs and amino acids are enriched in the asthmatic bronchial microbiome. Additionally, we observed that the bronchial microbiome among asthmatic subjects at baseline differed compositionally and functionally according to their responsiveness to treatment with ICSs.
Commonly reported microbial community metrics (eg, richness, evenness, and burden) did not differ significantly among our 3 groups. This is not unexpected due to the broad characterization of microbial composition provided by such measures; the interindividual heterogeneity of microbiota composition found in all human niches, including the lung 30 ; and the mild disease severity in our subjects. Considering the clinical homogeneity of our asthmatic group, their heterogeneity in bronchial bacterial composition is striking. Moreover, this heterogeneity was predominantly observed among subjects with T2-low asthma, in whom bronchial bacterial burden was significantly greater than in subjects with T2-high asthma. The trend toward higher bacterial phylogenetic diversity in our subjects with mild asthma suggests their lower airways are receptive to colonization by a wider variety of bacteria. Although we could not pinpoint any specific clinical features associated with this finding, additional contributing factors might include differences in previous environmental exposures, clearance of microorganisms, or other immune function parameters not identified here.
Reasons for the low bronchial bacterial burden in subjects with T2-high asthma are unclear, but the finding echoes a recent observation in subjects with severe asthma of an inverse relationship between bronchial bacterial burden and numbers of bronchial biopsy eosinophils. 4 A possible explanation is the bactericidal activity of more numerous airway eosinophils 31, 32 in subjects with T2-high airway inflammation. Given prior reports of inverse relationships between bacterial and fungal richness, 33, 34 the low bacterial burden in subjects with T2-high asthma could also reflect increased fungal or bacteriophage burden. Indeed, microbial interactions are not limited to bacteria because bacterial-viral interactions have been associated with asthma exacerbations and risk for asthma development. 35, 36 Such interkingdom interactions 37 should be considered in future studies. This study expands the list of bacterial groups previously associated with asthma, further supporting the idea that -corrected t test) . B, Taxa significantly enriched or depleted in relative abundance (at least 2-fold; q < 0.1, negative binomial regression) in ICS responders versus nonresponders. C, Predicted Kyoto Encyclopedia of Genes and Genomes pathways associated with xenobiotic biodegradation and metabolism in ICS responders and nonresponders. D, Taxa, differentially expressed (at least 2-fold; q < 0.1, zero-inflated negative binomial regression) in asthmatic subjects after ICS or placebo treatment.
alterations in microbial composition from a healthy state is a characteristic of asthma. Enrichment in certain Proteobacteria members (eg, Haemophilus and Neisseria species) among our ICS-naive asthmatic subjects resembles prior findings in ICS-using patients. [2] [3] [4] [5] [6] 28 However, we found other taxa discretely associated with asthma, including Fusobacterium and Porphyromonas species, 2 oral-associated anaerobes capable of augmenting pathogenic behavior of opportunistic respiratory pathogens, such as Pseudomonas aeruginosa. 38 Additionally, both Fusobacterium species 39 and Haemophilus species 40 induce MUC5AC expression in bronchial epithelial cells. Sphingomonodaceae represented another asthma-specific taxon the abundance of which, like that of Fusobacterium species, correlated with sputum eosinophilia. This finding echoed the reported activity of glycosphingolipids (present in the cell membrane of Sphingomonodaceae) in activating natural killer T cells to produce T2 cytokines [41] [42] [43] and the reported association of this bacterial family with bronchial reactivity. 5 Asthma-related alterations in bronchial microbiota composition also involve relative depletion in certain taxa, including members of the Lactobacillales. Numerous studies have demonstrated protective effects of certain Lactobacillus species strains against atopy through various mechanisms, including alteration of gastrointestinal 44 and respiratory tract 45, 46 permeability. Our finding that the predicted functions of the asthma-associated microbiota were relatively depleted in machinery for LPS biosynthesis suggests another possibility, since continuous stimulation of the airways with LPS has been shown to suppress T2 immune activation. 47 However, we propose that any ''proasthmatic'' activity of a bronchial microbiome is likely dependent on functional effects consequent to interactions among many microbiota members in the airway microenvironment rather than the activity of any one species. Microbiome-related functions indicated by our analyses as potentially enhanced in asthmatic subjects include increased capacity for metabolism of butyrate and propionate, SCFAs that maintain epithelial barrier function, and immune tolerance in the gut. [48] [49] [50] We speculate that use of anti-inflammatory SCFAs by members of the asthmatic airway microbiota might contribute to atopic asthma by reducing their bioavailability and the consequent capacity to downregulate host inflammatory responses to aeroallergens and pathogens.
Microbiome-related functions might also affect responsiveness to corticosteroid treatment. We found that pretreatment enrichment in asthma-associated Haemophilus, a genus with species previously shown to reduce response of BAL macrophages to corticosteroids, 2 was associated with diminished response to 6 weeks of treatment with inhaled fluticasone. Analysis of the predicted metagenome of the pretreatment bronchial microbiota present in ICS nonresponders also indicated enhancement of xenobiotic degradation capacity, which we hypothesize could contribute to their diminished response. In contrast, ICS-induced changes to the bronchial microbiota in ICS-responsive asthmatic subjects showed enrichment of previously reported asthma-associated taxa, such as Neisseria and Moraxella species. 2, 3, 6 Community shift detected in response to a lactose-containing placebo inhaler was not surprising because an influx of an additional sugar would be expected to alter the composition of microbial communities in the airways, favoring those species with the metabolic capacity to use such carbon sources. As importantly, these results emphasize the need to consider the effects of repeated inhalation of particles, especially of an ICS, as a selective pressure and nutritional source for airway microbiome members with the catalytic capacity to degrade such xenobiotics.
Perturbations to the bronchial microbiota associated with atopy alone are also a novel finding of this study. ANAs were less sensitized than AAs and showed primarily low T2 inflammation of bronchial epithelium. Although the greater severity of allergy in the AA group cannot be ruled out as contributing to the difference in bacterial signature observed between AAs and ANAs, distinct taxa associations with different markers of atopy and allergic inflammation were observed, suggesting that distinct microbial interactions with the host immune system occur in these 2 patient groups. These observations in ANAs support an association between airway colonization and atopy-related altered mucosal immune functions.
9,10 Atopy-specific taxa included members of the Pasteurellaceae (specifically Aggregatibacter and Haemophilus species). Members of Aggregatibacter are associated with periodontal disease driven by high proinflammatory cytokine (eg, TNF-a, IL-1b, IL-6, and IL-8) levels and reduced levels of IL-10. 51, 52 It is tempting to speculate that airway enrichment of this genus in ANAs could contribute to asthma protection through activation of the T1 arm of the immune system. We also highlight that specific taxa belonging to certain genera (eg, Prevotella and Haemophilus species) were associated with atopy only or asthma. This underscores the likely importance of species-or strain-level functional differences in microbial interactions related to disease status.
The limitations of our study include exclusive analysis of bacterial communities, the absence of nonatopic asthmatic subjects, and the relatively narrow breadth of asthma phenotype captured in this cohort. Moreover, our sample size was small in some comparisons, particularly in assessing changes in the bronchial microbiota in paired samples before and after ICS versus placebo treatment. However, strengths include the large number of subjects who were characterized and underwent invasive bronchoscopy to collect samples for analysis. Our study protocol also attended carefully to procedural and sampling methods to reduce contamination and analyze for possible contribution of nonbronchial sources of bacterial DNA to the data set.
In conclusion, our findings highlight the complexity of bacterial relationships to asthma in a background of atopy, conditions that are associated with distinct alterations in the airway microbiota. To achieve a comprehensive understanding of microbial factors involved in the induction of, management of, or protection against asthma, there is an important need to better understand functions collectively expressed by consortia of airway microbes, which could have a profound influence on asthma.
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